SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back




Title
: Emerging Challenges in Primary Care 2018 Miami, FL
Activity/Course #:
: 04.28.18PC

Cost:
: Free
Release/Start Date:
: Apr 28 2018
Expiration Date:
: Apr 28 2018
Topics:
: Primary Care Medicine
Target Audience:
: Primary Care Providers
Format:
: Live EC Primary Care
Estimated Time To Complete CME Activity:
: 6.0 hours
Credit(s):
: 6.0 AMA PRA Category I Credit(s)
6.0 AANP Contact hour(s) which includes 2.0 pharmacology hour(s)
Hardware/Software Requirements:
Saturday, April 28, 2018
Sheraton Miami Airport Hotel
3900 NW 21st Street
Miami, FL 33142
(305) 871-3800

Registration Fee

There is no registration fee for this activity.

Special Accommodations

NACE fully complies with the legal requirements of the Americans with Disabilities Act. Any activity registrant who feels s/he may need accommodations based on the impact of a disability should contact NACE to discuss your specific need.

Event Parking
A discounted self parking rate of $10.00 is available at the hotel.

Program Summary

Primary care providers face complex challenges everyday in their busy practices. With rapid changes in medicine, staying informed about new developments can be equally challenging. Our goal in this CME activity is to help you hone your skills in the diagnosis and management of patients with varied conditions you are likely encountering in your practice.

We have recruited a faculty of well-known thought leaders and experienced teachers who, as clinicians themselves, understand the challenges you face every day as a primary care provider. Our faculty will be at your disposal to provide evidence-based science, current treatment guidelines, discuss challenging cases, and provide answers for you that can ultimately lead to better health care for your patients. The presentations will include several interactive cases and discussion sessions to keep you actively learning.

Please join us and become an active participant in this one-day learning community of your peers.

Learning Objectives
At the conclusion of this program, participants should be able to:

  1. Describe the newer concepts in the pathophysiology of asthma and type 2 inflammation, and the implications of biologic therapies in the era of precision medicine; Determine the utility of simple biomarkers to identify patients who are candidates for targeted biologic therapies and appropriate referral; Discuss the impact of comorbid conditions on asthma control and the evidence-based approach to their treatment; Discuss the paradigms of multidisciplinary care in asthma, with an emphasis on patient and provider education, to improve adherence to inhalers and emerging biologic therapies in asthma.

  2. Review the risk factors and classification of pulmonary hypertension (PH); Discuss the appropriate diagnostic strategy for pulmonary arterial hypertension (PAH), including the roles of echocardiography, ventilation/perfusion (V/Q) scanning, and right heart catheterization (RHC); Review current and emerging treatments for patients with PAH; Describe how to monitor patients with PAH for disease progression.

  3. Recognize the pathogenesis of type 2 diabetes (T2DM) as a progressive, multi-defect disorder; Discuss the strengths and limitations of current guidelines for diabetes management; Successfully use strategies for adherence to multiple medications to improve outcomes in diabetes; Examine data on current combination strategies to choose therapies that most effectively address a patient's underlying pathophysiologic needs.

  4. Discuss clinician and patient barriers to initiation and intensification of insulin therapy; Recognize the prevalence and clinical impact of hypoglycemia in special populations at risk; Discuss the pharmacology and clinical differences between existing and new long-acting and concentrated insulins; Discuss how to incorporate new basal and concentrated insulins into clinical practice while minimizing the risk of adverse events.

  5. Understand the requirements of root-cause analysis study; Discuss ways to promote error reduction and prevention, while improving patient safety; Recognize the five most misdiagnosed conditions during the previous biennium.

 
Agenda*

7:30-8:00

  Continental Breakfast and Registration
8:00-8:10   Welcome Remarks
Gregg Sherman, MD
8:10-9:10  

The Role of Type 2 Inflammation in Severe Persistent Asthma: Integrating Biologic Therapy to Optimize Outcomes
Diego J. Maselli, MD FCCP

9:10-10:20  

Presentation Theatre: Long-Term Results of Treatment Across a Broad Range of Patients with Type 2 Diabetes (CME not offered)

10:20-11:20   Evolving Strategies of Care in Pulmonary Arterial Hypertension: Integrating the Data into Practice
Franck Rahaghi, MD, MHS, FCCP
11:20-12:20   The Progression of Type 2 Diabetes: A Rational Approach for Long Term Disease Management
Mark Stolar, MD
12:20-1:20  

Lunch (on your own)

1:20-2:20   Safely Achieving Goals in Type 2 Diabetes (T2DM): The Role of Concentrated and Long-Acting Insulins
Mark Stolar, MD
2:20-3:20  

Prevention of Medical Errors - Part I
Bernd Wollschlaeger, MD, FAAFP, FASAM

*Fulfills 2 hour Florida Requirement for physicians*

   3:20-3:30 Break
   3:30-4:30 

Prevention of Medical Errors - Part II
Bernd Wollschlaeger, MD, FAAFP, FASAM

*Fulfills 2 hour Florida Requirement for physicians*

   4:30-4:35 Summary of Key Points and Closing Remarks
 
*Agenda subject to change.


Faculty
Diego J. Maselli, MD FCCP
Assistant Professor of Medicine
Division of Pulmonary Diseases & Critical Care
University of Texas Health Science Center at San Antonio
Director, Respiratory Care, University Health System
Director, Severe Asthma Program, University Health System
San Antonio, TX

Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL

Mark Stolar, MD
Associate Professor of Clinical Medicine
Northwestern University Medical School
Chicago, IL

Bernd Wollschlaeger, MD, FAAFP, FASAM
Board Certified Family Physician and Addiction Specialist
Voluntary Clinical Assistant Professor University of Miami & Florida International University
Clinical Preceptor
Florida State University MD Program, Barry University PA Program &
Florida International University MD & ARNP Program
Miami, FL


Planning Committee
Gregg Sherman, MD
Chief Medical Officer/Course Director
National Association for Continuing Education
Plantation, FL


Sheila Lucas, CWEP
Activity Director
National Association for Continuing Education

Plantation, FL

Sandy Bihlmeyer, M.Ed.
National Association for Continuing Education

Plantation, FL

Michelle Frisch, MPH, CHCP
National Association for Continuing Education

Plantation, FL

Harvey C. Parker, Ph.D., CHCP
National Association for Continuing Education

Plantation, FL

Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 6 Contact hour(s) of continuing education which includes 2.0 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosure will be provided in the activity materials.
Commercial Support
This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., an educational grant from AstraZeneca Pharmaceuticals LP, an educational grant from Novo Nordisk Inc, and an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.